Mylan chief's pay tops $16M; Cephalon's drops to $11M

In a tale of two CEOs, we find one who got a raise and another whose pay dropped, though both managed to grow revenues in 2009. First, there's the fortunate Robert Coury (photo), CEO of Mylan, whose pay grew to almost $16.5 million. The boost was mostly because of changes in the value of his pension, Dow Jones reports, and nonqualified deferred compensation. His base salary grew by $70,000 to $1.57 million.

How'd Mylan do over that period? Well, its reported revenues dropped by about 1 percent to $5.09 billion. But a chunk of the prior year's revenues accounted for previously deferred revenue from the sale of drug rights. Net revenue for 2009 grew by 8 percent to $5.02 billion.

Then there's Cephalon chief Frank Baldino (photo). His pay dropped 24 percent to $11.1 million, BNet Pharma reports. And at his company, revenues grew 11 percent, to $2.152 billion, and adjusted net income rose by 28 percent to $469 million, beating its forecast.

Every company's different, and executive pay depends on different benchmarks. And it's true that last year, Baldino's pay came in for some criticism; his company's a lot smaller than the Big Pharma firms that pay their CEOs less. But allow us just one more comparison: Jet travel. As BNet points out, Baldino has to reimburse Cephalon for vacation travel on the company plane, and he did in 2009 to the tune of $63,835. Coury gets his for free as a perk; his travel cost the company $433,387 in 2009, up from $348,988 in 2008, Dow Jones reports. That's a lot of flying.

- get Mylan's SEC filing
- get the Dow Jones story
- see the Pittsburgh Post-Gazette's brief
- see Mylan's earnings release
- read the post at BNet Pharma
see Cephalon's SEC filing
- check out the Cephalon earnings release

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.